TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $10.50 Average PT from Analysts

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have been given a consensus rating of “Moderate Buy” by the five analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $10.50.

A number of analysts have weighed in on the company. Wall Street Zen downgraded TriSalus Life Sciences from a “hold” rating to a “sell” rating in a report on Sunday, September 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TriSalus Life Sciences in a research note on Wednesday, October 8th.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ TLSI opened at $4.39 on Friday. The company’s 50 day moving average price is $4.72 and its 200-day moving average price is $4.89. TriSalus Life Sciences has a 52-week low of $3.42 and a 52-week high of $5.88. The company has a market capitalization of $218.93 million, a P/E ratio of -3.72 and a beta of 0.47.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its earnings results on Thursday, November 13th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.79). TriSalus Life Sciences has set its FY 2025 guidance at EPS. Analysts forecast that TriSalus Life Sciences will post -1.55 earnings per share for the current year.

Institutional Trading of TriSalus Life Sciences

Several large investors have recently modified their holdings of the stock. Bank of America Corp DE increased its stake in TriSalus Life Sciences by 1.8% in the second quarter. Bank of America Corp DE now owns 188,906 shares of the company’s stock valued at $1,030,000 after purchasing an additional 3,374 shares in the last quarter. Connective Capital Management LLC grew its stake in shares of TriSalus Life Sciences by 12.8% in the 2nd quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock valued at $179,000 after buying an additional 3,717 shares during the period. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at about $29,000. JPMorgan Chase & Co. increased its position in TriSalus Life Sciences by 35,804.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after buying an additional 7,519 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in TriSalus Life Sciences during the 2nd quarter worth approximately $47,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.